Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23604237 | 1.00 | TSHR (0.42) | TSHRALDH1A1SLC7A5L3MBTL1SMN1; SMN2 | |
| SCHEMBL18075516 | 0.83 | TSHR (0.42) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 | |
| SCHEMBL18075518 | 0.83 | TSHR (0.42) | TSHRALDH1A1SLC7A5SMN1; SMN2SLC1A3 | |
| SCHEMBL24686867 | 0.81 | L3MBTL1 (0.44) | TSHRALDH1A1L3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL1287364 | 0.80 | SLC7A5 (0.54) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL21526182 | 0.80 | SLC7A5 (0.54) | SLC7A5NOS3NOS1NOS2SLC1A3 | |
| SCHEMBL563054 | 0.80 | TSHR (0.48) | TSHRALDH1A1SLC7A5L3MBTL1SMN1; SMN2 | |
| SCHEMBL21673199 | 0.80 | TSHR (0.43) | TSHRALDH1A1SLC7A5L3MBTL1SMN1; SMN2 | |
| SCHEMBL16086739 | 0.80 | TSHR (0.43) | TSHRALDH1A1SLC7A5L3MBTL1SMN1; SMN2 | |
| SCHEMBL7359844 | 0.80 | SLC7A5 (0.54) | TSHRALDH1A1SLC7A5MAPK1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | CD274, PDCD1LG2, PDCD1 | TSHR 566/4885ALDH1A1 538/4885SLC7A5 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.